Compare CLLS & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLLS | USNA |
|---|---|---|
| Founded | 1999 | 1992 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.3M | 317.0M |
| IPO Year | 2014 | 1996 |
| Metric | CLLS | USNA |
|---|---|---|
| Price | $3.93 | $17.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | 27.9K | ★ 83.0K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.58 |
| Revenue | N/A | ★ $1,060,902,000.00 |
| Revenue This Year | N/A | $3.90 |
| Revenue Next Year | $0.98 | $6.21 |
| P/E Ratio | ★ N/A | $29.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $16.60 |
| 52 Week High | $5.48 | $38.32 |
| Indicator | CLLS | USNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 41.04 |
| Support Level | $3.93 | $16.70 |
| Resistance Level | $4.48 | $18.11 |
| Average True Range (ATR) | 0.21 | 0.87 |
| MACD | -0.01 | -0.20 |
| Stochastic Oscillator | 66.67 | 17.22 |
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.